239 related articles for article (PubMed ID: 24147044)
1. Endogenous human MDM2-C is highly expressed in human cancers and functions as a p53-independent growth activator.
Okoro DR; Arva N; Gao C; Polotskaia A; Puente C; Rosso M; Bargonetti J
PLoS One; 2013; 8(10):e77643. PubMed ID: 24147044
[TBL] [Abstract][Full Text] [Related]
2. Disruption of the p53-Mdm2 complex by Nutlin-3 reveals different cancer cell phenotypes.
Arva NC; Talbott KE; Okoro DR; Brekman A; Qiu WG; Bargonetti J
Ethn Dis; 2008; 18(2 Suppl 2):S2-1-8. PubMed ID: 18646312
[TBL] [Abstract][Full Text] [Related]
3. Homozygous mdm2 SNP309 cancer cells with compromised transcriptional elongation at p53 target genes are sensitive to induction of p53-independent cell death.
Rosso M; Polotskaia A; Bargonetti J
Oncotarget; 2015 Oct; 6(33):34573-91. PubMed ID: 26416444
[TBL] [Abstract][Full Text] [Related]
4. Stress-induced alternative splice forms of MDM2 and MDMX modulate the p53-pathway in distinct ways.
Jacob AG; Singh RK; Comiskey DF; Rouhier MF; Mohammad F; Bebee TW; Chandler DS
PLoS One; 2014; 9(8):e104444. PubMed ID: 25105592
[TBL] [Abstract][Full Text] [Related]
5. A single nucleotide polymorphism in the MDM2 gene disrupts the oscillation of p53 and MDM2 levels in cells.
Hu W; Feng Z; Ma L; Wagner J; Rice JJ; Stolovitzky G; Levine AJ
Cancer Res; 2007 Mar; 67(6):2757-65. PubMed ID: 17363597
[TBL] [Abstract][Full Text] [Related]
6. Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors.
Chien WP; Wong RH; Cheng YW; Chen CY; Lee H
Ann Surg Oncol; 2010 Apr; 17(4):1194-202. PubMed ID: 19941079
[TBL] [Abstract][Full Text] [Related]
7. A p53-independent role of Mdm2 in estrogen-mediated activation of breast cancer cell proliferation.
Brekman A; Singh KE; Polotskaia A; Kundu N; Bargonetti J
Breast Cancer Res; 2011 Jan; 13(1):R3. PubMed ID: 21223569
[TBL] [Abstract][Full Text] [Related]
8. The role of miR-18b in MDM2-p53 pathway signaling and melanoma progression.
Dar AA; Majid S; Rittsteuer C; de Semir D; Bezrookove V; Tong S; Nosrati M; Sagebiel R; Miller JR; Kashani-Sabet M
J Natl Cancer Inst; 2013 Mar; 105(6):433-42. PubMed ID: 23365201
[TBL] [Abstract][Full Text] [Related]
9. Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients.
Schmidt MK; Tommiska J; Broeks A; van Leeuwen FE; Van't Veer LJ; Pharoah PD; Easton DF; Shah M; Humphreys M; Dörk T; Reincke SA; Fagerholm R; Blomqvist C; Nevanlinna H
Breast Cancer Res; 2009; 11(6):R89. PubMed ID: 20021639
[TBL] [Abstract][Full Text] [Related]
10. Estrogen-activated MDM2 disrupts mammary tissue architecture through a p53-independent pathway.
Kundu N; Brekman A; Kim JY; Xiao G; Gao C; Bargonetti J
Oncotarget; 2017 Jul; 8(29):47916-47930. PubMed ID: 28615518
[TBL] [Abstract][Full Text] [Related]
11. The MDM2-a splice variant of MDM2 alters transformation in vitro and the tumor spectrum in both Arf- and p53-null models of tumorigenesis.
Volk EL; Fan L; Schuster K; Rehg JE; Harris LC
Mol Cancer Res; 2009 Jun; 7(6):863-9. PubMed ID: 19491200
[TBL] [Abstract][Full Text] [Related]
12. Oroxylin A promotes PTEN-mediated negative regulation of MDM2 transcription via SIRT3-mediated deacetylation to stabilize p53 and inhibit glycolysis in wt-p53 cancer cells.
Zhao K; Zhou Y; Qiao C; Ni T; Li Z; Wang X; Guo Q; Lu N; Wei L
J Hematol Oncol; 2015 Apr; 8():41. PubMed ID: 25902914
[TBL] [Abstract][Full Text] [Related]
13. Protein phosphatase 1 nuclear targeting subunit is a hypoxia inducible gene: its role in post-translational modification of p53 and MDM2.
Lee SJ; Lim CJ; Min JK; Lee JK; Kim YM; Lee JY; Won MH; Kwon YG
Cell Death Differ; 2007 Jun; 14(6):1106-16. PubMed ID: 17318220
[TBL] [Abstract][Full Text] [Related]
14. Phosphorylation of Daxx by ATM contributes to DNA damage-induced p53 activation.
Tang J; Agrawal T; Cheng Q; Qu L; Brewer MD; Chen J; Yang X
PLoS One; 2013; 8(2):e55813. PubMed ID: 23405218
[TBL] [Abstract][Full Text] [Related]
15. Development and structural characterisation of human scFv targeting MDM2 spliced variant MDM2
Lim CC; Chan SK; Lim YY; Ishikawa Y; Choong YS; Nagaoka Y; Lim TS
Mol Immunol; 2021 Jul; 135():191-203. PubMed ID: 33930714
[TBL] [Abstract][Full Text] [Related]
16. Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer.
Lukas J; Gao DQ; Keshmeshian M; Wen WH; Tsao-Wei D; Rosenberg S; Press MF
Cancer Res; 2001 Apr; 61(7):3212-9. PubMed ID: 11306511
[TBL] [Abstract][Full Text] [Related]
17. Ribosomal proteins RPL37, RPS15 and RPS20 regulate the Mdm2-p53-MdmX network.
Daftuar L; Zhu Y; Jacq X; Prives C
PLoS One; 2013; 8(7):e68667. PubMed ID: 23874713
[TBL] [Abstract][Full Text] [Related]
18. Association of breast cancer outcome with status of p53 and MDM2 SNP309.
Boersma BJ; Howe TM; Goodman JE; Yfantis HG; Lee DH; Chanock SJ; Ambs S
J Natl Cancer Inst; 2006 Jul; 98(13):911-9. PubMed ID: 16818855
[TBL] [Abstract][Full Text] [Related]
19. Expression of alternatively spliced mdm2 transcripts correlates with stabilized wild-type p53 protein in human glioblastoma cells.
Kraus A; Neff F; Behn M; Schuermann M; Muenkel K; Schlegel J
Int J Cancer; 1999 Mar; 80(6):930-4. PubMed ID: 10074928
[TBL] [Abstract][Full Text] [Related]
20. The regulation of MDM2 oncogene and its impact on human cancers.
Zhao Y; Yu H; Hu W
Acta Biochim Biophys Sin (Shanghai); 2014 Mar; 46(3):180-9. PubMed ID: 24389645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
